Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Profit After Tax (2022 - 2025)

Entrada Therapeutics has reported Profit After Tax over the past 4 years, most recently at -$39.2 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$39.2 million for Q4 2025, down 3562.78% from a year ago — trailing twelve months through Dec 2025 was -$143.8 million (down 319.04% YoY), and the annual figure for FY2025 was -$143.8 million, down 319.04%.
  • Profit After Tax for Q4 2025 was -$39.2 million at Entrada Therapeutics, up from -$44.1 million in the prior quarter.
  • Over the last five years, Profit After Tax for TRDA hit a ceiling of $55.0 million in Q2 2024 and a floor of -$44.1 million in Q3 2025.
  • Median Profit After Tax over the past 4 years was -$19.5 million (2022), compared with a mean of -$11.2 million.
  • Biggest five-year swings in Profit After Tax: soared 452.05% in 2024 and later plummeted 3562.78% in 2025.
  • Entrada Therapeutics' Profit After Tax stood at -$24.6 million in 2022, then soared by 61.22% to -$9.5 million in 2023, then surged by 111.85% to $1.1 million in 2024, then plummeted by 3562.78% to -$39.2 million in 2025.
  • The last three reported values for Profit After Tax were -$39.2 million (Q4 2025), -$44.1 million (Q3 2025), and -$43.1 million (Q2 2025) per Business Quant data.